Only rivastigmine isthe most selective for BChE and is particularly suitable for moderateto severe AD, among FDA-approved anticholinesterase drugs. However, in addition to side effects such asnausea, vomiting, diarrhea, stomach pain, anorexia, and weight loss,17–35% of patients experienced delusions, hallucinations, agitationand aggression, disinhibition, irritability and lability, and abnormalmotor behavior. Consequently, the explorationof potential BChE inhibitor candidates for the management of AD hasbecome imperative. Here, BCHE is linked to Alzheimer disease.